annual cash & cash equivalents:
$173.73M-$39.85M(-18.66%)Summary
- As of today (September 16, 2025), RARE annual cash & cash equivalents is $173.73 million, with the most recent change of -$39.85 million (-18.66%) on December 31, 2024.
- During the last 3 years, RARE annual cash & cash equivalents has fallen by -$133.85 million (-43.52%).
- RARE annual cash & cash equivalents is now -75.65% below its all-time high of $713.53 million, reached on December 31, 2020.
Performance
RARE Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$496.62M-$6.30M(-1.25%)Summary
- As of today (September 16, 2025), RARE quarterly cash & cash equivalents is $496.62 million, with the most recent change of -$6.30 million (-1.25%) on June 30, 2025.
- Over the past year, RARE quarterly cash & cash equivalents has dropped by -$273.37 million (-35.50%).
- RARE quarterly cash & cash equivalents is now -59.04% below its all-time high of $1.21 billion, reached on December 31, 2020.
Performance
RARE quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RARE Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.7% | -35.5% |
| 3 y3 years | -43.5% | -8.6% |
| 5 y5 years | -59.9% | -39.0% |
RARE Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.5% | +30.7% | -44.1% | +18.7% |
| 5 y | 5-year | -75.7% | +30.7% | -59.0% | +18.7% |
| alltime | all time | -75.7% | +2239.2% | -59.0% | +830.4% |
RARE Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $496.62M(-1.3%) |
| Mar 2025 | - | $502.92M(-18.5%) |
| Dec 2024 | $173.73M(-18.7%) | $616.83M(-1.7%) |
| Sep 2024 | - | $627.78M(-18.5%) |
| Jun 2024 | - | $769.99M(+84.0%) |
| Mar 2024 | - | $418.38M(-27.8%) |
| Dec 2023 | $213.58M(+60.7%) | $579.22M(+30.4%) |
| Sep 2023 | - | $444.07M(-19.8%) |
| Jun 2023 | - | $553.68M(-12.3%) |
| Mar 2023 | - | $631.32M(-15.7%) |
| Dec 2022 | $132.94M(-56.8%) | $748.62M(-15.8%) |
| Sep 2022 | - | $889.19M(+63.7%) |
| Jun 2022 | - | $543.31M(-9.2%) |
| Mar 2022 | - | $598.54M(-19.1%) |
| Dec 2021 | $307.58M(-56.9%) | $740.20M(-0.9%) |
| Sep 2021 | - | $747.12M(-12.7%) |
| Jun 2021 | - | $855.76M(-12.3%) |
| Mar 2021 | - | $976.10M(-19.5%) |
| Dec 2020 | $713.53M(+64.6%) | $1.21B(+58.2%) |
| Sep 2020 | - | $766.37M(-5.9%) |
| Jun 2020 | - | $814.26M(+22.7%) |
| Mar 2020 | - | $663.44M(-12.2%) |
| Dec 2019 | $433.58M | $755.39M(+43.3%) |
| Sep 2019 | - | $527.22M(-14.8%) |
| Jun 2019 | - | $618.45M(-13.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $715.67M(+55.6%) |
| Dec 2018 | $113.43M(+12.9%) | $459.98M(-8.7%) |
| Sep 2018 | - | $503.75M(-8.0%) |
| Jun 2018 | - | $547.78M(+1.1%) |
| Mar 2018 | - | $541.89M(+130.6%) |
| Dec 2017 | $100.49M(-37.6%) | $234.95M(-36.8%) |
| Sep 2017 | - | $371.53M(-7.1%) |
| Jun 2017 | - | $400.11M(-6.0%) |
| Mar 2017 | - | $425.46M(+11.5%) |
| Dec 2016 | $161.12M(+72.2%) | $381.56M(-4.1%) |
| Sep 2016 | - | $397.84M(+1.2%) |
| Jun 2016 | - | $393.29M(-4.8%) |
| Mar 2016 | - | $413.15M(-5.5%) |
| Dec 2015 | $93.57M(+284.7%) | $437.15M(-2.5%) |
| Sep 2015 | - | $448.38M(+37.1%) |
| Jun 2015 | - | $327.10M(-4.8%) |
| Mar 2015 | - | $343.64M(+83.3%) |
| Dec 2014 | $24.32M(+227.5%) | $187.49M(-6.8%) |
| Sep 2014 | - | $201.19M(+31.3%) |
| Jun 2014 | - | $153.27M(-7.3%) |
| Mar 2014 | - | $165.40M(+209.9%) |
| Dec 2013 | $7.43M(-91.4%) | $53.38M(-16.1%) |
| Sep 2013 | - | $63.66M(-10.3%) |
| Jun 2013 | - | $71.00M(-17.6%) |
| Dec 2012 | $86.19M(+709.7%) | $86.19M |
| Dec 2011 | $10.64M | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of RARE is $173.73M
What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual cash & cash equivalents is $713.53M
What is Ultragenyx Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
Over the past year, RARE annual cash & cash equivalents has changed by -$39.85M (-18.66%)
What is Ultragenyx Pharmaceutical Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of RARE is $496.62M
What is the all time high quarterly cash & cash equivalents for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly cash & cash equivalents is $1.21B
What is Ultragenyx Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, RARE quarterly cash & cash equivalents has changed by -$273.37M (-35.50%)